Research
Hormonal
Obesity heritability is estimated at 40-70%, driven by over 1000 genetic variants and complex interactions with environmental and epigenetic factors, with early-onset severe obesity strongly linked to specific genetic mutations.
Recognize that obesity has a strong biological basis, with heritability estimates up to 70%. For those with early-onset severe obesity, genetic factors play a major role. This understanding supports the use of targeted therapies and early screening rather than relying solely on lifestyle advice.
GoodSupportsHIGH confidence
Based on family studies, twin studies, and adoption studies, estimated heritability of body mass index (BMI) can reach 40%-70%. Over 1000 variants of gene loci, including single-nucleotide polymorphisms (SNPs), are significantly associated with obesity... early-onset, severe obesity is strongly driven by genetic factors.
Why this rating
The paper cites established family/twin studies and genomic findings, representing strong consensus in the field.
Source
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Chantal Mathieu et al. · European Journal of Endocrinology · 2025
DOI 10.1093/ejendo/lvaf065
narrative_reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Monogenic diabetes, representing 1-4% of diabetes cases in infants and young adults, is frequently misdiagnosed as Type 1 or Type 2 diabetes, leading to inappropriate therapeutic management and worsened prognosis.Moderate
- The gut microbiota causally influences obesity and metabolic disorders by modulating the secretion of gut hormones (GLP-1, ghrelin, PYY) and influencing hypothalamic neuroendocrine pathways, suggesting microbiota-based therapies as a potential treatment.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →